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Abstract — Prion diseases are incurable and fatal neurodegenerative disorders 
that affect both humans and animals. The causative agent is an infectious 
protein called prion (PrPSc), which is the pathological form of a normal protein 
(PrPC) present on the cell membrane. The molecular mechanisms underlying 
prion replication and subsequent degeneration of the Central Nervous System 
(CNS) are still poorly understood and therefore innovative approaches are 
needed to build diagnostic, therapeutic, taxonomic, and disease surveillance 
tools. We are going to adopt an unbiased genomic approach and conduct 
whole transcriptome analyses using microarray gene expression methods in 
brain and/or blood of infected animals versus healthy controls. We hope to 
identify a set of genes that can be used for early diagnosis and/or as targets 
for therapeutic strategies. Within the Trans2Care project we intend to promote 
collaboration and exchange of knowledge to facilitate all partners’ research 
objectives, and possibly find a common way to accelerate the process aimed at 
improving our healthcare system.
Index Terms — prion, prion protein, neurodegeneration, gene expression, 
genomics.
———————————————————
1 SISSA, INTERNATIONAL SChOOL FOR ADVANCED STUDIES
SISSA, International School for Advanced Studies was established in Trieste in 1978, and it is one of the leading scientific institutions in Italy for postgraduate 
training in Mathematics, Neuroscience and Physics. There are thirteen Ph.D. courses 
available, covering the three main research areas, three professional master’s courses 
and, thanks to an agreement with University of Trieste and University of Trento, three 
joint curricula for master’s degrees (laurea magistrale) in Mathematics, Physics and 
Neuroscience. Besides being a school, SISSA is also an international research center 
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with financial support granted by private and public entities (Friuli Venezia Giulia 
Region, Italian Government and European Research Council). In 2010-2011 alone, 
Italian funding amounted to some € 5.5 million, while international grants provided 
over € 10 million. The Neuroscience Department (hereafter Department) is built on 
Cognitive Neuroscience and Neurobiology. The Cognitive Neuroscience group focuses 
on how the brain generates behavior (language, perception, action) using methods 
from artificial neural networks to human neuropsychology. The Neurobiology 
component of the Department is devoted to research on the nervous system, using a 
combination of molecular, cellular and integrative approaches. One specialized division 
of the Neurobiology area is devoted to the study of neurodegenerative diseases (such 
as Alzheimer’s, Parkinson’s, Huntington’s and Prion diseases), focusing on Functional 
and Structural Genomics. The Prion Biology Laboratory is part of the Genomics branch 
of the Department.
2 ThE PRION BIOLOGy LABORATORy
The Prion Biology Laboratory currently includes one associate professor, four post-doctoral fellows, nine Ph.D. students and two undergraduate students. We have 
a Biosafety Level 2 facility with a cell culture room as well as protein expression and 
purification equipment. In addition, we have access to core facilities and technologies 
available in the Department such as an animal facility carrying transgenic animals, 
histology room, DNA sequencing, confocal microscopy, Real-Time PCR and Affymetrix 
micro-array platforms.
The laboratory is supported by various grants and organizations such as IIT, PRIN, 
FIRB, FP7, and so on. Just to mention one example, recently € 5 million were 
granted to our laboratory and another group in the same Department to identify the 
changes in the human genome leading to a number of incurable neurodegenerative 
diseases (FIRB-Programme agreements 2011; project title: Functional Genomics of 
Neurodegenerative Diseases). Within this same line of research we became partners 
of the international strategic project Trans2Care, FESR 2007-2013 for the cooperation 
between Italy and Slovenia.
2.1 Research Activities
The focus of the Prion Biology Laboratory is studying prion diseases, rare and fatal neurodegenerative maladies that affect humans and animals, for which there is 
no diagnostic tool, nor a cure [1, 2]. In mammals, prions reproduce by recruiting the 
normal, cellular isoform of the prion protein (PrPC) and stimulating its conversion 
into the disease-causing isoform (PrPSc). PrPC and PrPSc have the same amino acid 
sequence, but distinct conformations: PrPC is rich in αα-helical content and has little 
αβ-sheet structure, whereas PrPSc has less αα-helical content and is rich in αβ-sheet 
structure (Fig. 1). The conformational conversion of PrPC to PrPSc is the fundamental 
event underlying prion diseases, and it is still poorly understood. The main research 
lines of the laboratory are: therapy of prion disease [3], physiology of the prion protein 
[4], syntethic prions and molecular determinant to infectivity [5], structural biology 
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and biophysics of the prion protein [6], transcriptomics and neurodegeneration [7], 
molecular mechanisms of neurodegeneration [8].
The project funded by the Trans2care grant is focused on the analysis of the whole 
transcriptome of animal models affected by prion disease. The goal is identifying genes 
that can become potential targets for diagnostic and/or therapeutic approaches. 
Our collaborators identified some candidate genes by microarray gene expression 
analyses in brain tissue of a primate model of prion disease and they appear to be 
very promising. Our objective is validating these candidates using a more sensitive 
and accurate technology such as qRT-PCR. A second model we are using is cattle 
infected with BSE (Bovine Spongiform Encephalopathy or mad cow disease). In this 
case the tissue is blood and we are performing some QC tests of the samples before 
embarking in the microarray gene expression analysis and subsequent validation 
with qRT-PCR. 
Recent findings support the idea that neurodegenerative diseases may all share a 
common mechanism that implies a prion-like behavior. Therefore, even though prion 
diseases are rare disorders, basic research on their mechanisms may be useful to 
explain all the neurodegenerative maladies, like Alzheimer’s and Parkinson’s disease, 
that affect large portions of the world population.
Fig.1. The conformational conversion of PrPC (A) to PrPSc (B).
3 ROLES IN TRANS2CARE
3.1  What we can offer to T2C
We have focused our research projects on exploring the infection mechanisms of prions from various angles; therefore we have gained expertise in many fields, 
from protein expression and purification to animal models, as well as gene expression 
analyses. We can provide T2C partners with our knowledge to facilitate the exchange 
of expertise within the network, and at the same time we can take advantage of other 
partners’ technological skills to further understand prion replication mechanisms and 
subsequent degeneration of the CNS. We have in fact an ongoing collaboration with 
ZTM - Blood Transfusion Centre of Slovenia (PP10) that we intend to exploit further. 
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So far PP10 has developed a panel of mAbs against different moieties of the prion 
protein and some of them can distinguish and differentiate between the wild type 
PrPC and its pathogenic form PrPSc. They will be tested in our laboratory mainly for 
the detection of PrP in immunohistochemical procedures (i.e. Western Blot, ELISA 
and IF), but they may also become important diagnostic and/or therapeutic tools. 
We are trying to expand this collaboration in the direction of targeted proteomics 
using Multiple Reaction Monitoring assays (MRM Proteomics). In this way markers 
obtained by transcriptomic analyses could be directly screened at the protein level in 
samples of either animal models or patients.
We are going to seek additional opportunities to collaborate with other project 
partners.
4. CONCLUSIONS
The aim of the Prion Biology Laboratory is conducting high level research in the field of neurodegeneration and in particular unraveling aspects of prion diseases that 
are still poorly understood. Within the Trans2Care framework, we intend to employ 
gene expression profiling methods to identify gene candidates that may become 
potential diagnostic biomarkers and/or therapeutic targets. The participation in 
the Trans2Care initiative can be very helpful in opening new collaborations with the 
partners or expanding existing ones that may lead to joint discoveries and publications. 
In addition, having the opportunity of interacting with such diverse partners ranging 
from basic research institutes to technology centers and clinics, may foster exchange 
of ideas that can lead to potential technology transfer opportunities to improve our 
healthcare system.
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